Valiant Laboratories Limited is an India-based pharmaceutical ingredient manufacturing company. The Company is focused on manufacturing a Paracetamol active pharmaceutical ingredient (API)/bulk drug. It has several applications in the treatment of conditions such as headache, muscle ache, arthritis, backache, toothache, cold and fever. It is also used in the management of severe pain such as post-surgical and cancer pain. It operates a single-location manufacturing facility on the Tarapur industrial estate.
VALIANT LABORATORIES LTD Financial Highlights
- Revenue: VALIANT LABORATORIES LTD reported revenue of ₹239.79 crore in FY26 vs ₹138.81 crore in FY25. It showed an increase of 72.75% on a yearly basis.
- Operating Profit: VALIANT LABORATORIES LTD reported an operating profit of ₹0.77 crore in FY26 vs ₹1.51 crore in FY25. It showed an increase of 150.99% on a year-on-year basis.
- Net Profit: VALIANT LABORATORIES LTD reported a net loss of ₹3.27 crore in FY26 vs ₹2.20 crore in FY25. It showed a decrease of 48.64% on a yearly basis.
VALIANT LABORATORIES LTD Quarterly Result Highlights
- VALIANT LABORATORIES LTD reported revenue of ₹92.15 crore in Mar 2026, compared with ₹53.09 crore in Dec 2025, representing an increase of 73.57% on a quarter-on-quarter (QoQ) basis.
- VALIANT LABORATORIES LTD reported an operating profit of ₹1.05 crore in Mar 2026, compared with ₹2.99 crore in Dec 2025, representing an increase of 135.12% on a quarter-on-quarter (QoQ) basis.
- VALIANT LABORATORIES LTD reported a profit of ₹1.76 crore in Mar 2026, compared with ₹7.06 crore in Dec 2025, reflecting an increase of 124.93% on a QoQ basis.
- The earnings per share (EPS) of VALIANT LABORATORIES LTD stood at ₹0.51 during Mar 2026.